Pairing GLP-1 medications with strength training and high-protein diets may help reduce this risk, but its not always enough
In trials, individuals using Semaglutide GLP-1 for weight management achieved average weight reductions of around 1015% of their body weight over the course of 68 weeks when combined with healthy eating and regular physical activity
Its active ingredient is semaglutide, which belongs to a class of drugs called glucagon-like peptide-1 (GLP-1) receptor agonists
A drug that achieves more than 22% weight loss, demonstrated across two pivotal trials in distinct populations, with a well-characterised safety profile, would until recently have been considered an exceptional result
REDEFINE (obesity) and REIMAGINE (T2D) are the main Phase 3 programs, with REDEFINE 1, 2, and 4 already reported